top of page

Obstructive Sleep Apnea and Cardiovascular Disease

A Scientific Statement From the American Heart Association

Yerem Yeghiazarians, MD, FAHA, Chair; Hani Jneid, MD, FAHA, Vice Chair; Jeremy R. Tietjens, MD; Susan Redline, MD; Devin L. Brown, MD, MS, FAHA; Nabil El-Sherif, MD; Reena Mehra, MD; Biykem Bozkurt, MD, PhD, FAHA; Chiadi Ericson Ndumele, MD, PhD, FAHA; Virend K. Somers, MD, PhD, FAHA; on behalf of the American Heart Association

Council on Clinical Cardiology; Council on Peripheral Vascular Disease; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; Stroke Council; and Council on Cardiovascular Surgery and Anesthesia

ABSTRACT: Obstructive sleep apnea (OSA) is characterized by recurrent complete and partial upper airway obstructive events, resulting in intermittent hypoxemia, autonomic fluctuation, and sleep fragmentation. Approximately 34% and 17% of middleaged

men and women, respectively, meet the diagnostic criteria for OSA. Sleep disturbances are common and underdiagnosed among middle-aged and older adults, and the prevalence varies by race/ethnicity, sex, and obesity status. OSA prevalence is as high as 40% to 80% in patients with hypertension, heart failure, coronary artery disease, pulmonary hypertension,

atrial fibrillation, and stroke. Despite its high prevalence in patients with heart disease and the vulnerability of cardiac patients to OSA-related stressors and adverse cardiovascular outcomes, OSA is often underrecognized and undertreated in cardiovascular practice. We recommend screening for OSA in patients with resistant/poorly controlled hypertension,

pulmonary hypertension, and recurrent atrial fibrillation after either cardioversion or ablation. In patients with New York Heart Association class II to IV heart failure and suspicion of sleep-disordered breathing or excessive daytime sleepiness, a formal sleep assessment is reasonable. In patients with tachy-brady syndrome or ventricular tachycardia or survivors of sudden cardiac death in whom sleep apnea is suspected after a comprehensive sleep assessment, evaluation for sleep apnea should be considered. After stroke, clinical equipoise exists with respect to screening and treatment. Patients with nocturnally occurring angina, myocardial infarction, arrhythmias, or appropriate shocks from implanted cardioverter-defibrillators may be especially likely to have comorbid sleep apnea. All patients with OSA should be considered for treatment, including behavioral modifications and weight loss as indicated. Continuous positive airway pressure should be offered to patients with severe OSA, whereas oral appliances can be considered for those with mild to moderate OSA or for continuous positive airway pressure–intolerant patients. Follow-up sleep testing should be performed to assess the effectiveness of treatment.

AHA Statement OSA and Cardiovascular Disease
Download PDF • 914KB

2 views0 comments

Recent Posts

See All

Rio is an amazing place for a World Sleep Meeting

Dear Board Members, Scientific Committee Members and Associates of the World Dentofacial Sleep Society, We hope this email finds you well in good health and high spirits. We are thrilled to share som


Board members reviewed the Blog name submissions and the overwhelming majority preferred a title offered by Tom Colquit! Congratulations. Tom wins the tequila!!! And his winning name for the BLOG is

BLOG names submitted:

Pulmonaut, Excelsior, Hub, Snapchat, In Good Compaanny, Grand Central, Nucleus, Polestar, Convergence, Navel, Wise Grasshopper, Dots, Vortex, Coopetition, TrueNorth If you have more ideas please submi


bottom of page